Successful Conclusion of 19th China International Peptide Symposium

From July 4 to 8, 2026, the 19th China International Peptide Symposium (CPS2026), held in conjunction with the 16th International Peptide Symposium, took place in Beijing, China. As one of the most influential academic conferences in the global peptide science community, this edition attracted over 1,000 scientists, industry representatives, and young researchers from more than 30 countries and regions, including China, the United States, Europe, Japan, and South Korea.

Under the theme "Convergent Innovation, Peptides Empowering a Better Life," the conference featured a rich program of plenary lectures, invited talks, oral presentations, and poster sessions. The scientific agenda spanned peptide synthesis methodology, peptide drug discovery and development, peptide chemical biology, peptide materials and nanotechnology, peptide vaccines and immunotherapy, and cyclic and constrained peptide chemistry, among other cutting-edge topics.

Peptide therapeutics, with their high target specificity, low toxicity, and favorable pharmacokinetic profiles, are emerging as a hot direction in drug discovery. At this conference, topics such as the continued evolution of GLP-1 receptor agonists, the rapid development of peptide-drug conjugates (PDCs), and neoantigen peptide vaccines for cancer immunotherapy sparked lively discussions. Leading international scholars shared breakthrough results in cyclic peptide drug design, oral peptide delivery technologies, and AI-assisted peptide drug discovery, signaling a new wave of innovation across the peptide pharmaceutical industry.

In the methodology sessions, microwave-assisted peptide synthesis for difficult sequences, eco-friendly solvent alternatives guided by green chemistry principles, and the next generation of automated high-throughput peptide synthesizers were focal points of discussion. With growing pharmaceutical demand for peptide drugs, large-scale, high-efficiency industrial SPPS technology is gaining critical importance. Multiple presentations emphasized the pivotal role of the automated peptide synthesizer in accelerating drug candidate screening and preclinical research.

This year’s conference placed special emphasis on fostering academia-industry interaction. Leading peptide pharmaceutical companies, CRO/CDMO service providers, and peptide synthesizer manufacturers from around the world set up exhibition booths, showcasing the complete technology chain from R&D to industrialization. Multiple corporate technical seminars and industry-academia roundtable dialogues were held, covering topics such as the challenges of peptide drug commercialization, scale-up strategies, and GMP compliance.

As a biotech company specializing in the R&D and manufacturing of peptide synthesizers, Peptide Scientific Inc. participated in CPS2026 as an exhibitor. At its booth, the company spotlighted the PepAxis™-Nova3 automated peptide synthesizer. Supporting flexible configurations of 2, 4, or 6 channels with independent parallel or asynchronous synthesis modes, the Nova3 is purpose-built for peptide drug screening, structure-activity relation (SAR) studies, peptide library construction, and other advanced peptide research applications.

Throughout the conference, the live demonstration of Nova3 attracted researchers from universities, institutes, and pharmaceutical companies alike. Attendees praised the instrument’s high-precision quantitative dispensing system, independent channel parameter configuration, and fully automated intelligent operation. The Peptide Scientific team engaged in in-depth, face-to-face discussions with visitors on peptide synthesis technology trends, laboratory automation needs, and efficient strategies for custom peptide synthesis, laying a strong foundation for future collaborations.

Beyond academic presentations and exhibitions, CPS2026 featured a variety of special side events. The Young Scientists Forum provided early-career peptide researchers with a stage to present their work; the Best Poster Award competition encouraged active participation from graduate students and postdoctoral fellows; and the conference banquet offered a relaxed and friendly atmosphere for networking, fostering cross-disciplinary and cross-border scientific friendships.

CPS2026 not only showcased the latest achievements in peptide science but also built a valuable platform for exchange and collaboration within the global peptide research community. From innovative peptide drugs targeting protein-protein interactions to smart-responsive peptide nanomaterials, from chemical synthesis to biosynthesis, peptide science is pushing boundaries across multiple dimensions. With the continuing maturation of AI-assisted design, green synthesis technologies, and novel delivery systems, peptides are poised to play an increasingly important role in medicine and healthcare, functional materials, and fundamental life science research.

The scientific outcomes and industry insights from this conference will continue to drive collaborative innovation in the global peptide field. The next China International Peptide Symposium will be held in 2028 — together, we look forward to the next milestone in peptide science.

Peptide Scientific Inc. is a high-tech enterprise dedicated to the design, R&D, and manufacturing of peptide synthesizers. Operating under the PepAxis™ brand, the company embraces the philosophy of "Innovation at the Core" and "Precision Engineering Meets Lab Efficiency." Peptide Scientific offers a complete SPPS product line spanning research-scale, pilot-scale, and industrial-scale solutions — including the Nova Series, Atlas Series, Sirius industrial-scale synthesizer, Aquila peptide cleavage system, and Tetras high-throughput synthesis platform — providing one-stop peptide synthesis system solutions for university laboratories, pharmaceutical companies, and biotech firms worldwide.